Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 3 1

Status

Completed 4Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 4NIH 2OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gynecologic 31Genitourinary 25Breast 19Gastrointestinal 17Thoracic 9Tumor-Agnostic 7Sarcoma 6Other solid neoplasm 4Classical hematology 4Myeloid 3Lymphoid 3CNS 3Other hematologic neoplasm 2Head & Neck 1Endocrine 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Neoplasms, Unknown Primary 1Carcinoma 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Has results × olaparib × Tumor-Agnostic × Clear all
NCT03842228 2026-05-29

COD

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04197713 2026-04-29

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

National Cancer Institute (NCI)

Phase 1 Active not recruiting
13 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT03976362 2026-02-25

KEYLYNK-008

Merck Sharp & Dohme LLC

Phase 3 Completed
851 enrolled 25 charts
Tumor-Agnostic

Carcinoma

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated
67 enrolled 10 charts
Tumor-Agnostic

Neoplasms

NCT02093351 2019-10-02

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

AstraZeneca

Phase 1 Completed
79 enrolled 35 charts
Tumor-Agnostic

Neoplasms

NCT01813474 2018-01-16

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
23 enrolled 15 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡